[A20-88] Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V
Last updated 04.01.2021
Project no.:
A20-88
Commission:
Commission awarded on 01.10.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
| Adults with previously untreated chronic lymphocytic leukaemia (CLL) |
Result of dossier assessment:
| Patients in good general health for whom therapy with fludarabine + cyclophosphamide + rituximab is an option: indication of major added benefit. Other research questions: added benefit not proven. |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-78 | Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-77 | Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-60 | Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-39 | Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-04 | Ibrutinib - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G14-11 | Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A23-04 | Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V | Commission completed |